Skip to main content
. Author manuscript; available in PMC: 2018 Sep 6.
Published in final edited form as: Cancer Immunol Immunother. 2017 Jan 11;66(5):647–656. doi: 10.1007/s00262-016-1952-0

Figure 2.

Figure 2

Evolution of injected lesions in a patient over time. A CR is observed at week 36 after beginning of treatment. In most lesions, a vitiligo-like depigmentation develops over time, as a consequence of a strong antimelanoma immunity that also targets healthy melanocytes, because of shared expression of melanocyte differentiation antigens. Data from the literature have shown that development of a vitiligo-like depigmentation in patients with melanoma may be associated with more favorable clinical outcome [61].